Abstract
Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal cancer and 24 non–small cell lung cancer formalin-fixed paraffin-embedded tissue specimens identified at least one clinically relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorectal cancer sample and KIF5B-RET in a lung adenocarcinoma. Further screening of 561 lung adenocarcinomas identified 11 additional tumors with KIF5B-RET gene fusions (2.0%; 95% CI 0.8–3.1%). Cells expressing oncogenic KIF5B-RET are sensitive to multi-kinase inhibitors that inhibit RET.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Forbes, S.A. et al. Nucleic Acids Res. 39, D945–D950 (2011).
Lièvre, A. et al. Cancer Res. 66, 3992–3995 (2006).
Di Nicolantonio, F. et al. J. Clin. Oncol. 26, 5705–5712 (2008).
Wertz, I.E. et al. Nature 471, 110–114 (2011).
Turner, N., Tutt, A. & Ashworth, A. Curr. Opin. Pharmacol. 5, 388–393 (2005).
Wilson, C.H., McIntyre, R.E., Arends, M.J. & Adams, D.J. Oncogene 29, 4567–4575 (2010).
Engelman, J.A. et al. Nat. Med. 14, 1351–1356 (2008).
Soda, M. et al. Nature 448, 561–566 (2007).
Kwak, E.L. et al. N. Engl. J. Med. 363, 1693–1703 (2010).
Pao, W. et al. PLoS Med. 2, e17 (2005).
Chapman, P.B. et al. N. Engl. J. Med. 364, 2507–2516 (2011).
Pao, W. et al. Proc. Natl. Acad. Sci. USA 101, 13306–13311 (2004).
Vassilev, L.T. et al. Science 303, 844–848 (2004).
Finn, R.S. et al. Breast Cancer Res. 11, R77 (2009).
Toogood, P.L. et al. J. Med. Chem. 48, 2388–2406 (2005).
Di Nicolantonio, F. et al. J. Clin. Invest. 120, 2858–2866 (2010).
Wang, Y. et al. Blood 114, 5024–5033 (2009).
Wong, D.W. et al. Cancer 117, 2709–2718 (2011).
Fusco, A. et al. Nature 328, 170–172 (1987).
Henderson, Y.C., Ahn, S.H., Kang, Y. & Clayman, G.L. Clin. Cancer Res. 14, 4908–4914 (2008).
Acknowledgements
We would like to thank M. Hawryluk for his help in preparing this manuscript. This work is supported by the Dana Farber/Harvard Cancer Center Lung Cancer SPORE P50 CA090578 (P.A.J.), the Cammarata Family Foundation Research Fund (M.C. and P.A.J.), the Nirenberg Fellowship at the Dana-Farber Cancer Institute (M.C. and P.A.J.) and the Japan Society for the Promotion of Science (JSPS), grant references 23659674, 21390394 and 21591820 (H.S.).
Author information
Authors and Affiliations
Contributions
D.L. and R.Y. designed experiments and algorithms, and performed analyses. J.W. and G.M.F. performed data analyses. A.P. and G.O. performed RNA preparations and prepared the cDNA libraries and sequencing. M.J. designed the experiments and performed analyses. J.A.C. and K.C.M. performed laboratory and project management. S.R.D. and T.B. performed tissue pathology preparations and extractions. J.S.R. provided tissue specimens and the pathology review. S.B., K.W.B., A.D., L.G., F.J., E.W. and Z.Z. performed DNA library preparation and sequencing. P.J.S., M.T.C. and P.A.J. designed experiments, analyzed data and wrote the manuscript. T.P., H.N., L.-S.G., C.E.S., J.K., H.S., H.R.K. and S.P. provided subject specimens. M.C. performed genotyping of subjects with lung cancer, conducted in vitro studies and analyzed data. D.E. performed in vitro studies.
Corresponding authors
Ethics declarations
Competing interests
D.L., R.Y., G.O., A.P., M.J., J.A.C., S.B., T.B., K.W.B., A.D., S.R.D., G.M.F., L.G., F.J., K.C.M., E.W., J.W., Z.Z., M.T.C. and P.J.S. are employees of Foundation Medicine, Inc. J.S.R. is a consultant to Foundation Medicine, Inc.
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Figures 1–3 and Supplementary Tables 1–5 (PDF 3500 kb)
Rights and permissions
About this article
Cite this article
Lipson, D., Capelletti, M., Yelensky, R. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18, 382–384 (2012). https://doi.org/10.1038/nm.2673
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2673
This article is cited by
-
Recent progress of small-molecule of RET inhibitors against Non-small cell lung cancer
AAPS Open (2024)
-
MTAP-ANRIL gene fusion promotes melanoma epithelial-mesenchymal transition-like process by activating the JNK and p38 signaling pathways
Scientific Reports (2023)
-
The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients
Journal of Cancer Research and Clinical Oncology (2023)
-
Preclinical Pharmacokinetics and in vitro Metabolism of FHND5071, a Novel Selective RET Kinase Inhibitor
European Journal of Drug Metabolism and Pharmacokinetics (2023)
-
RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
Journal of Translational Medicine (2022)